SAR443809
/ Sanofi
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
March 22, 2024
A Study to Test if SAR443809 is Tolerated and Safe When Taken as a Single Dose in Healthy Adults
(clinicaltrials.gov)
- P1 | N=54 | Completed | Sponsor: Sanofi
New P1 trial • Complement-mediated Rare Disorders • Hematological Disorders • Paroxysmal Nocturnal Hemoglobinuria • Rare Diseases
March 11, 2023
SAR443809: A Selective Inhibitor of the Complement Alternative Pathway, Targeting Complement Factor Bb.
(PubMed, Blood Adv)
- "Finally, intravenous and subcutaneous administration of the antibody in nonhuman primates demonstrated sustained inhibition of complement activity for several weeks following injection. Overall, SAR443809 shows strong potential for treatment of alternative pathway-mediated disorders."
Journal • Complement-mediated Rare Disorders • Hematological Disorders • Paroxysmal Nocturnal Hemoglobinuria • Rare Diseases • CFB
1 to 2
Of
2
Go to page
1